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Introduction
Immunological mechanisms are increasingly implicated in the pathogenesis of depressive symptoms 1, 2 . Activation of the peripheral immune system has been consistently associated with major depressive disorder 3 . However, it has also been anticipated that not all patients with MDD will be peripherally inflamed to the same extent. A deeper understanding of how peripheral immune biomarkers relate to some of the dimensions of clinical heterogeneity encompassed by a diagnosis of MDD could be an important step towards mechanistically stratified treatment of depression in the future 2, 4 .
C-reactive protein (CRP) is an acute phase protein that is widely used in clinical practice and has also been measured in many prior studies of MDD. A high sensitivity assay for CRP is well validated and accessible. CRP synthesis is induced in the liver by pro-inflammatory cytokines -especially interleukin 6 (IL-6) -in response to infection, inflammation and tissue damage. In a meta-analysis of 20 case-control studies 3 , CRP was moderately increased "on average" (Cohen's d = 0.47) in patients with MDD. However, there was significant heterogeneity of effect size between studies that may be attributable to clinical heterogeneity, with greater CRP in severe depression (Cohen's d = 0.50) than in mild/moderate depression (Cohen's d = 0.37), as well as methodological differences between studies 5 .
We were motivated to test the hypothesis that the clinically defined subgroup of patients with treatment-resistant depression would have the most abnormally increased CRP. An association between treatment resistance to monoaminergic anti-depressant drugs and increased CRP is hypothetically predictable on clinical and mechanistic grounds. Clinical studies indicate that pro-inflammatory cytokines that induce CRP synthesis are increased in treatment-resistant MDD. Pro-inflammatory cytokines can reduce the extracellular availability of serotonin by biasing expression of genes related to serotonin transport and tryptophan metabolism 6, 7 . Single studies have also reported that elevated CRP may be associated with other dimensions of clinical heterogeneity, viz atypical depression, childhood adversity, higher numbers of previous depressive episodes, or anxiety in male patients 2 .
We measured CRP in four groups of participants: currently depressed but not medicated (untreated) MDD patients; currently depressed and medicated (treatment-resistant) patients; currently medicated but not depressed (treatment-responsive) patients; and healthy volunteers with no history of MDD or monoaminergic drug treatment. The primary 5 CRP-related clinical phenotypes of depression Chamberlain et al (2017) 13 th September 2017 hypothesis, that CRP would be most clearly increased above normal levels in treatmentresistant patients with MDD, was tested by planned analyses of between-group differences in mean CRP. In a secondary analysis, we took a more exploratory approach to the question of what other dimensions of clinical heterogeneity in the sample might be related to variation in CRP. We used the multivariate technique of partial least squares (PLS) to explore the relationships between CRP and multiple (139) clinical phenotypes -ranging from BMI to questionnaire items for depressive symptoms, anxiety states or history of childhood adversity 8, 9 . In this way, we could identify a subset of clinical phenotypes weighted strongly on latent dimensions of clinical heterogeneity that were predictive of higher CRP levels. We also tested the confirmatory hypothesis that scores on these clinical dimensions of peripheral inflammation would be higher in the subgroup of patients with treatment resistance defined a priori. 
Patients and Methods
This was a non-interventional study, conducted as part of the Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's disease (NIMA). There were five clinical study centres in the UK: Brighton, Cambridge, Glasgow, King's College London, and Oxford. All procedures were approved by an independent Research Ethics Committee (National Research Ethics Service East of England, Cambridge Central, UK) and the study was conducted according to the Declaration of Helsinki. All participants provided informed consent in writing, and received £100 compensation for taking part.
Sample and eligibility criteria
We recruited four groups of participants: treatment-resistant depression, treatmentresponsive depression, untreated depression, and healthy volunteers.
For all participants, the following inclusion criteria applied: age 25-50 years, able to give informed consent; able to fast for 8 hours, and abstain from strenuous exercise for 72h, prior to venous blood sampling; and fluent English. The following exclusion criteria applied: pregnancy or breast feeding; alcohol or substance use disorder in the preceding 12 months; participation in an investigational drug study within the preceding 12 months; lifetime history of any medical disorder or current use of any medication (e.g. statins, corticosteroids, antihistamines, anti-inflammatory medications) likely to compromise interpretation of CRP (see Patients were assigned to one of three subgroups or strata, per protocol: (i) treatmentresistant (DEP+MED+) patients who had total HAM-D > 13 and had been medicated with a 7 CRP-related clinical phenotypes of depression Chamberlain et al (2017) 13 th September 2017 monoaminergic drug at a therapeutic dose for at least six weeks; (ii) treatment-responsive (DEP-MED+) patients who had total HAM-D < 7 and had been medicated with a monoaminergic drug at a therapeutic dose for at least six weeks; and (iii) untreated (DEP+MED-) patients who had HAM-D > 17 and had not been medicated with a monoaminergic drug for at least six weeks. Cut-offs were defined a priori based on the literature. Total HAM-D score > 17 is a standard threshold for entry into placebo-controlled treatment trials of MDD; whereas a lower threshold of total HAM-D > 13 is typically used to define treatment-resistant depression, because there is usually some modest symptomatic response to treatment even if patients remain depressed 10, 11 .
A group of healthy volunteers was recruited by advertising with no current or past history of any major psychiatric disorder as defined by DSM-5, and no history of monoaminergic drug treatment for any indication. Healthy volunteers completed the same screening and baseline assessments as patient groups (see below).
Age, gender, medical history, smoking status, and family history were documented by semistructured clinical interviews. Height and weight were measured for calculation of BMI (kg/m 2 ).
Questionnaire assessments
Psychological symptoms and childhood adversity were assessed by administration of the following questionnaires (see Supplemental Information): the Beck depression inventory;
the Spielberger State-Trait Anxiety Rating scale; the Chalder Fatigue Score; the Snaith-Hamilton Pleasure Scale; and the Childhood Trauma Questionnaire.
High sensitivity CRP measurement
High sensitivity C-reactive protein was measured as one of many immunological markers in a venous blood sample drawn from each participant. Here, we focus on CRP since this is convenient, and has been widely used 2 . Participants fasted for 8h, and abstained from strenuous exercise for 72h, prior to venous blood sampling between 08:00-10:00am. For analysis of between-group differences in hs-CRP and other variables we first compared all MDD participants to healthy volunteers using planned t-tests. We then evaluated pairwise group differences using post-hoc t-tests, provided the main effect of group was significant by one-way analysis of variance (ANOVA). When assumptions of normality were violated, transforms and/or non-parametric tests were used. Cohen's d was reported for the effect size of hs-CRP corrected for BMI in each clinical group compared to healthy volunteers.
Statistical analysis
Additionally, we compared the proportion of participants in each group who had clinically elevated CRP, defined as > 3mg/L 12, 13 . The threshold for statistical significance was defined as two-tailed P < 0.05 throughout.
To identify demographic and clinical phenotypes associated with variation in CRP across all study participants, we utilized the method of partial least squares (PLS), as implemented in JMP Pro software Version 13.0 14 . PLS is a multivariate technique for modelling relationships between a set of predictor (X) and response (Y) variables in terms of a set of mutually orthogonal latent factors, or PLS components 9 . Detailed methodology is provided in 
Results

Demographic and clinical data
The size of each group and their demographic and clinical characteristics are summarized in Table 1 . The groups did not differ significantly in terms of demographic characteristics. As expected, post hoc tests indicated that each group differed significantly from each other group on HAM-D total score (least significant t = 4.19, df = 248, P < 0.001). The mean number of failed pharmacological treatments for MDD episodes (<75% symptomatic response, defined by ATRQ) is listed for each clinical group in Table 1 . The treatmentresistant group had more failed treatments than the untreated group (Wilcoxon Z = 2.843, P = 0.005); both the treatment-resistant group and the untreated group had significantly more failed treatments than the treatment-responsive group (Wilcoxon Z = 5.794, P < 0.001 and Wilcoxon Z = 3.079, P = 0.002, respectively). The majority of treatment-resistant patients were taking selective serotonin reuptake inhibitors (see Table 1 footnote). Summary statistics for questionnaire-based measures and comorbidities are provided in Tables S1
and S2.
C-reactive protein
Mean hs-CRP concentrations (and 95% confidence intervals) are shown in Table 1 . Mean CRP was significantly increased in all MDD cases compared to healthy controls (Wilcoxon Z = 2.7, P = 0.007). Both treatment-resistant and treatment-responsive groups had significantly higher mean hs-CRP than controls (Wilcoxon Z = 2.9, P = 0.004 and Wilcoxon Z = 2.6, P = 0.010, respectively).
The proportion of participants with hs-CRP levels exceeding the conventional threshold value of 3mg/L was also significantly different between the pooled MDD groups and controls The distributions of hs-CRP were positively skewed (moment skewness = 5.08) and therefore were normalized by base 10 log transform; see Figure 1 . Log 10 CRP was significantly increased in all MDD cases compared to controls (t = 2.81, df = 250, P = 0.004).
Only the treatment-resistant and treatment-responsive cases had significantly higher log 10 CRP than controls (t = 3.07, df = 248, P = 0.002 and t = 2.32, df = 248, P = 0.021, respectively).
As anticipated by prior studies, there was a significant positive correlation between BMI and log 10 CRP across all study participants (Spearman's rho = 0.56, df = 250, P < 0.001; Figure   1 ). Since BMI data were also positively skewed (moment skewness = 1.03) 15 , we regressed log 10 CRP on log 10 BMI and used the residuals as estimates of BMI-corrected CRP (Figure   1 ). BMI-corrected CRP was significantly elevated in all MDD cases compared to controls (t = 2.24, df = 238, P = 0.026). Post hoc t-tests indicated that only the treatment-resistant cases had significantly higher mean BMI-corrected CRP than the controls (t = 2.71, df = 236, P = 0.007; Cohen's d = 0.47).
To assess the possible confounding effect of symptom severity, we identified the subgroup of treatment-resistant patients (N=48) that had total HAM-D > 17, thereby corresponding to the cut-off used to define the untreated group. We confirmed that BMI-corrected CRP was abnormally increased in treatment-resistant patients with HAM-D > 18 (t = 3.0, P = 0.004) with a case-control difference of similar size (Cohen's d = 0.43) to that of treatment-resistant patients with HAM-D > 13.
Partial least squares analysis of the relationship between CRP and clinical variables
Thirteen (out of 139) clinical phenotypes passed criterion for an important effect on CRP levels. Iterative cross-validation of the PLS model including only these important variables yielded an optimal two-factor solution (Figure 2 and S2) , which accounted in total for 34.7% Positive scores on PLS 2 indicated lower CRP. PLS2 scores differed significantly between groups (F = 24.34, df = 3,248, P < 0.001; Figure S3 ). Untreated patients had the highest 
Discussion
This is the first study to measure peripheral C-reactive protein using the same high sensitivity assay across a large sample of MDD patients (N=198) prospectively stratified in terms of their current and past history of treatment with monoaminergic antidepressant drugs. We replicated the well-established finding that CRP is significantly increased "on average" in MDD patients, screened for physical comorbidity, and compared to healthy volunteers matched for age, sex, BMI and cigarette smoking status. However, we also found evidence for our primary hypothesis that CRP was most abnormally increased in the subgroup of patients with treatment-resistant depression (N=102). The standardized size of the case-control difference in CRP between healthy volunteers and treatment-resistant cases (Cohen's d = 0.47) was greater than the case-control difference for treatmentresponsive cases (0.29), or untreated cases (0.18). Controlling for non-normality of the CRP distribution, and for the strong positive correlation between CRP and obesity, we found that the case-control difference in CRP remained significant only for the subgroup of treatmentresistant cases. These results of planned analysis are consistent with the hypothesis that peripheral inflammation is a marker or risk factor for treatment-resistant depression.
Taking a convergent but more exploratory approach to the data, we used multivariate analysis to identify two dimensions of clinical heterogeneity that were predictive of CRP. We found that a subset of 15 out of 131 clinically measured phenotypes explained ~36% of the variance in CRP. High BMI, high scores on vegetative symptoms of depression, low scores on calmness, and a history of childhood adversity, were all predictive of increased CRP. As expected from the results of our primary analysis, we confirmed that the group of patients defined a priori in terms of treatment resistance had the highest scores on this clinical profile associated with high CRP.
Treatment-resistant depression and peripheral inflammation
Monoamine reuptake inhibitors and related drugs are evidence-based pharmacological treatments for MDD; but response failure afflicts approximately 30% of patients 16 previously, although there is evidence both for increased pro-inflammatory cytokine concentrations 2 and for increased peripheral expression of cytokine related genes 17 in treatment-resistant depression. There is also some evidence that baseline inflammatory markers may be useful predictors of treatment response in MDD 18 . In a rat model of treatment-resistant depression, elevated CRP at baseline differentiated responders from non-responders to ketamine, an NMDA receptor antagonist with anti-inflammatory and antidepressant effects 19 . At a cellular level, neurons, microglia and macrophages respond to inflammatory challenges by activating metabolic pathways that reduce the synaptic availability of serotonin and catalyse the conversion of tryptophan to kynurenine and its putatively neurotoxic, glutamatergic agonist metabolites 7 . These effects of inflammation on serotonin transport and tryptophan metabolism may constitute a mechanism by which peripheral inflammation is associated with lack of therapeutic response to SSRIs 20 .
Clinical phenotypes predictive of increased CRP in depression
Obesity and its cardiovascular sequelae have been repeatedly associated with increased CRP. In the current study, which excluded patients with a lifetime history of medical disorders including atherosclerosis and diabetes, we confirmed that higher BMI was strongly associated with higher CRP levels. One mechanistic explanation is that macrophages constitute up to 60% of cells in adipose tissue and can release large amounts of IL-6, which is a key driver of CRP synthesis 21 . So it is not surprising that inflammation (CRP) and obesity (BMI) were related herein; however, we do not consider that this association trivially accounts for increased CRP in treatment-resistant depression. The groups did not differ significantly in baseline BMI and the case-control difference remained significant for the treatment-resistant patients even after statistical regression to control for individual differences in BMI.
Of all the depressive symptoms measured, so-called vegetative symptoms (psychomotor retardation, insomnia, difficulty getting started / difficulty working) were more important in explaining higher CRP. These findings are consistent with prior reports that somatic but not cognitive symptoms of depression were associated with increased CRP 22 . Vegetative symptoms of depression are akin to the illness or sickness behavior that has been repeatedly demonstrated in animal models and experimental medicine studies of humans exposed to acute pro-inflammatory challenge 23 . We also found evidence that state anxiety 14 CRP-related clinical phenotypes of depression Chamberlain et al (2017) 13 th September 2017 was related with CRP, which is compatible with prior data linking acute endotoxin exposure to anxious and depressive states in healthy volunteers 24 .
It is established that childhood trauma increases risk of later mental health disorders, including depression 25 . In a meta-analysis, individuals exposed to childhood trauma had significantly elevated levels of CRP in adulthood, albeit with a small effect size (Fisher's Z = 0.10) 26 . In a longitudinal study of female adolescents at risk of depression, childhood adversity was found to promote subsequent clustering of depression and inflammation 27 .
These results are compatible with our findings that feeling unloved in childhood and wanting to change one's family in childhood were significantly correlated with higher CRP in adults.
Methodological issues
Due to the case-control design, between-group differences in CRP could theoretically be confounded by other factors influencing peripheral inflammation. However, we excluded patients with inflammatory disorders or anti-inflammatory drug treatment; and the groups were matched for demographic characteristics. The lack of statistically significant casecontrol differences in BMI-corrected CRP for the comparisons between healthy volunteers and the treatment-responsive and untreated MDD groups could theoretically reflect the smaller sizes of these groups compared to the treatment-resistant MDD group. However, power calculations indicated that the case-control differences in BMI-corrected CRP would probably not have been significant even if the treatment-responsive group had the same size as the resistant group ( Table 1) . The depression symptom severity threshold or cut-off score for the treatment-resistant group was HAM-D > 13, whereas the cut-off score for the untreated group was HAM-D > 18 10, 11 . Potentially the resulting difference in symptom severity between these groups could explain the greater increase of CRP in the treatmentresistant group compared to controls. However, matching the cut-off used for the untreated group made little difference to the primary results. Treatment resistance was defined by inadequate response to the current drug treatment whereas some other criteria for treatment resistance stipulate failed response to at least two drugs of different mechanisms of action.
The study was not planned or powered to test differences in CRP between subgroups defined by dose or type of current anti-depressant medication. The sample was recruited from the UK population, which is known to differ from the US and other populations in terms of BMI and other factors that can influence the numerical distribution of CRP and this may mitigate generalizability of our results. Finally, CRP is only one of many markers of peripheral inflammation that have been, or could be, linked to depression. Although these CRP-related clinical phenotypes of depression Chamberlain et al (2017) 13 th September 2017 data demonstrate that CRP is robustly associated with treatment-resistant depression, we do not claim that CRP is necessarily the best of all possible peripheral blood biomarkers of treatment-resistant depression.
Conclusions
Major depressive disorder is associated with increased CRP compared to healthy volunteers and the case-control difference is greatest in treatment-resistant depression. Increased CRP and treatment resistance were also associated with other aspects of clinical heterogeneity in depression including obesity, vegetative symptoms of fatigue and sleep disturbance, state anxiety, and a history of childhood adversity. We suggest there may be a clinically and immunologically diagnosable sub-syndrome of "inflamed depression" comprising the MDD patients most likely to benefit therapeutically from second-line treatment with antiinflammatory drugs 13 . # The majority of treatment-resistant patients were taking selective serotonin reuptake inhibitors (SSRIs; 70%) with smaller numbers exposed to noradrenergic and specific serotonergic reuptake inhibitors (NSRIs; 15%), mixed reuptake inhibitors (25%), tricyclic antidepressants (4%), mood stabilizers (4%) and dopamine receptor antagonists (3%). Treatment-responsive patients were likewise predominantly treated with SSRIs (85%), followed by NSRIs (11%), mixed reuptake inhibitors (25%), or tricyclic antidepressants (4%). 
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